The Greater Cannabis Company, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
March 26, 2021 at 09:29 pm IST
Share
The Greater Cannabis Company, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was USD 48,044 compared to USD 7,120 a year ago. Operating loss was USD 294,457 compared to USD 525,323 a year ago. Net loss was USD 951,170 compared to USD 1.648 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.05 a year ago.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.